These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 24599933)

  • 21. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
    Beltran PJ; Calzone FJ; Mitchell P; Chung YA; Cajulis E; Moody G; Belmontes B; Li CM; Vonderfecht S; Velculescu VE; Yang G; Qi J; Slamon DJ; Konecny GE
    Clin Cancer Res; 2014 Jun; 20(11):2947-58. PubMed ID: 24727326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A HIF-1alpha-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells.
    Thomas R; Kim MH
    Prostate; 2009 Feb; 69(3):263-75. PubMed ID: 19016246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
    Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.
    Beltran PJ; Mitchell P; Chung YA; Cajulis E; Lu J; Belmontes B; Ho J; Tsai MM; Zhu M; Vonderfecht S; Baserga R; Kendall R; Radinsky R; Calzone FJ
    Mol Cancer Ther; 2009 May; 8(5):1095-105. PubMed ID: 19366899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
    Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
    J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
    Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Takaoka M; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
    Oncol Rep; 2008 Dec; 20(6):1473-7. PubMed ID: 19020730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
    Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
    Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
    [No Abstract]   [Full Text] [Related]  

  • 29. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
    Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.
    Min Y; Adachi Y; Yamamoto H; Imsumran A; Arimura Y; Endo T; Hinoda Y; Lee CT; Nadaf S; Carbone DP; Imai K
    Gut; 2005 May; 54(5):591-600. PubMed ID: 15831900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
    Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
    Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ID1 Controls Aggressiveness of Salivary Gland Cancer Cells via Crosstalk of IGF and AKT Pathways.
    Sumida T; Kamata YU; Kobayashi Y; Ishikawa A; Mori Y
    Anticancer Res; 2016 Aug; 36(8):3865-70. PubMed ID: 27466488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
    Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
    Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
    Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
    Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
    Cao L; Yu Y; Darko I; Currier D; Mayeenuddin LH; Wan X; Khanna C; Helman LJ
    Cancer Res; 2008 Oct; 68(19):8039-48. PubMed ID: 18829562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.
    Bao XH; Takaoka M; Hao HF; Wang ZG; Fukazawa T; Yamatsuji T; Sakurama K; Sun DS; Nagasaka T; Fujiwara T; Naomoto Y
    Anticancer Res; 2012 Jul; 32(7):2827-34. PubMed ID: 22753744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
    Breinig M; Mayer P; Harjung A; Goeppert B; Malz M; Penzel R; Neumann O; Hartmann A; Dienemann H; Giaccone G; Schirmacher P; Kern MA; Chiosis G; Rieker RJ
    Clin Cancer Res; 2011 Apr; 17(8):2237-49. PubMed ID: 21372220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor.
    Forest A; Amatulli M; Ludwig DL; Damoci CB; Wang Y; Burns CA; Donoho GP; Zanella N; Fiebig HH; Prewett MC; Surguladze D; DeLigio JT; Houghton PJ; Smith MA; Novosiadly R
    Mol Cancer Res; 2015 Dec; 13(12):1615-26. PubMed ID: 26263910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.